SLC5A2 and diabetic kidney disease: SGLT2 inhibitors for DKD should be initiated at the dose with evidence ofcardiorenal benefit (ie, canagliflozin 100 mg daily, dapagliflozin 10 mgdaily, empagliflozin 10 mg daily [the doses used in the prospective kidneytrials; note that the dosing may have been different in earlier CV outcometrials]).